XML 51 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements - Summary of Operating Expenses Category Related to Collaboration Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net reimbursement from Biogen reflected in the condensed consolidated statement of operations and comprehensive loss:        
Research and development expenses $ (83,497) $ (74,078) $ (207,723) $ (211,008)
Selling, general and administrative expenses (48,706) (35,099) (131,899) (143,454)
Total operating costs and expenses 132,334 $ 108,797 340,088 $ 382,764
Biogen Collaboration Agreement [Member]        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Expenses related to the Biogen Collaboration Agreement incurred by Sage 50,950   149,653  
Net reimbursement from Biogen reflected in the condensed consolidated statement of operations and comprehensive loss:        
Research and development expenses (21,634)   (63,843)  
Selling, general and administrative expenses (2,551)   (8,780)  
Total operating costs and expenses $ 26,765   $ 77,030